FOLH1 and neuroendocrine neoplasm: Subsequent translational research led to the development of more specific tracers such as radiolabeled somatostatin receptor (SSTR) targeting agents and prostate-specific membrane antigen (PSMA) ligands, which have successfully been incorporated into modern-day management practices of neuroendocrine tumors and prostate cancer, respectively [5].